Damora Therapeutics, Inc.
Moat Score — Damora Therapeutics, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 2 / 5 | Damora's core science relies on provisional (not yet issued) U.S. patent applications filed by Paragon Therapeutics covering mutCALR antibody compositions for DMR-001 and DMR-002, with potential expiry around 2046 if granted. The underlying rights sit under an option-and-license agreement rather than company-owned IP, and the DMR-002/DMR-003 options are still unexercised, limiting durability versus a company with granted, wholly-owned patents. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Damora owns no manufacturing facilities and outsources all development, manufacturing, and testing to third parties, so it has no structural cost edge over competitors. Its only 'cost advantage' is a strong balance sheet (~$257.6M cash at YE2025, ~$535M pro forma after the Feb 2026 offering) that buys more development runway than typical peers, which is a financing advantage rather than an operating cost advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | The company is pre-revenue with no approved or commercial product, so it currently exercises zero pricing power. Any future pricing power would depend on clinical proof-of-concept data for DMR-001 (expected starting mid-2027) that does not yet exist. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | As a clinical-stage biopharmaceutical with no marketed product, platform, or user base, Damora exhibits no network effects of any kind; value does not compound with additional users, prescribers, or patients the way it would for a platform business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | There are no current customers or prescribers to retain, so switching costs are effectively nonexistent today. If DMR-001 is eventually approved as a genetically targeted therapy for mutCALR-driven ET/MF, physician and patient inertia around established agents like ruxolitinib or hydroxyurea could create modest future switching dynamics, but this is speculative and unrealized. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Mutant-calreticulin-driven MPNs are a defined but not especially small genetic subpopulation, and multiple well-funded competitors (Incyte, Janssen, Meiji Seika, Prelude, Alethio) are pursuing the same mechanism in parallel, so there is little evidence of a market too small to support only one or two efficient incumbents. No efficient-scale dynamic protects Damora from well-capitalized rivals entering the same niche. |